
At BIO 2026, Thermo Fisher Scientific's Paul Jorjorian highlighted late-stage raw material switches as being among the most disruptive and underestimated risks in biopharma development.
Paul serves as the Vice President, Development & Scientific Solutions at Thermo Fisher Scientific. In his role he responsible for defining the research and development, process & analytical development, and MSAT strategy for the Drug Substance business.
Prior to that, he has been responsible for six biologics drug substances manufacturing and development sites located globally as Vice President Biologics. Additionally, he has held a number of roles with increasing responsibility in process development, manufacturing, and technology transfer. Before joining Thermo Fisher in 2014, he has worked for Gallus BioPharmaceuticals, Bristol-Myers Squibb and GE Plastics.
Paul holds a B.S. in Chemical Engineering and Management from Purdue University, IN and a Masters in Chemical Engineering from Cornell University, NY.

At BIO 2026, Thermo Fisher Scientific's Paul Jorjorian highlighted late-stage raw material switches as being among the most disruptive and underestimated risks in biopharma development.